NASDAQ:MBRX
Moleculin Biotech Inc Stock News
$4.76
-0.0200 (-0.418%)
At Close: May 10, 2024
Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended June 30, 2020
11:30am, Wednesday, 12'th Aug 2020
Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, ann
Here's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation
01:13pm, Tuesday, 11'th Aug 2020
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Moleculin Biotech (MBRX) Gets a Buy Rating from Maxim Group - Markets
03:30pm, Wednesday, 22'nd Jul 2020
In a report released yesterday, Jason McCarthy from Maxim Group assigned a Buy rating to Moleculin Biotech (MBRX – Research
Dow, S&P close higher as Covid-battered stocks surge, but off session’s best levels as tech sector sinks
09:24pm, Tuesday, 21'st Jul 2020
U.S. stock-indexes finish mostly higher Tuesday, but off the session’s best levels, as investors snap up beaten-down energy and financial stocks amid a slate...
Coronavirus update: U.S. case tally climbs above 3.8 million; President Trump appears to have changed his view on face masks
08:11pm, Tuesday, 21'st Jul 2020
The number of confirmed cases of the coronavirus illness COVID-19 in the U.S. rose above 3.8 million on Tuesday, and President Donald Trump appeared to...
Moleculin Pops 33% On Anti-Viral Activity For Potential Covid-19 Treatment
01:59pm, Tuesday, 21'st Jul 2020
Moleculin Biotech (MBRX) on Tuesday announced that a second round of independent laboratory testing has confirmed the antiviral activity of its drug candidate WP1122 as a potential treatment against c
Moleculin Shares Jump on Progress With Virus-Drug Candidate
01:36pm, Tuesday, 21'st Jul 2020
Moleculin Biotech says independent testing confirms the antiviral activity of its coronavirus treatment candidate.
Moleculin Biotech says second lab test found antiviral activity for potential COVID-19 treatment
12:30pm, Tuesday, 21'st Jul 2020
Shares of small-cap Moleculin Biotech Inc. undefined soared 43% in premarket trade Tuesday, after the company said a second round of laboratory testing...
Moleculin Biotech says second lab test found antiviral activity for potential COVID-19 treatment
11:46am, Tuesday, 21'st Jul 2020
Shares of small-cap Moleculin Biotech Inc. soared 43% in premarket trade Tuesday, after the company said a second round of laboratory testing confirmed antiviral activity for WP1122, its candidate as
Moleculin Announces New Independent In Vitro Testing Confirms Antiviral Activity of WP1122 in Coronavirus
11:30am, Tuesday, 21'st Jul 2020
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses,
Moleculin Biotech (NASDAQ:MBRX) Shares Gap Down to $1.07
01:54am, Sunday, 19'th Jul 2020
Moleculin Biotech Inc (NASDAQ:MBRX) shares gapped down before the market opened on Friday . The stock had previously closed at $1.11, but opened at $1.07. Moleculin Biotech shares last traded at $1.03
Moleculin Biotech (MBRX) Gets a Buy Rating from Maxim Group - Markets
05:06pm, Thursday, 16'th Jul 2020
In a report released yesterday, Jason McCarthy from Maxim Group assigned a Buy rating to Moleculin Biotech (MBRX – Research
Moleculin Surges on Manufacturing Deal for Coronavirus Therapy
03:11pm, Thursday, 16'th Jul 2020
Moleculin (MBRX) signs an agreement with Sterling Pharma Solutions for manufacturing and supply of WP1122, which is being developed as potential treatment for COVID-19.
Moleculin Announces Agreement to Produce WP1122 for Expanded Development of Potential COVID-19 and Oncology Drug Candidate
11:30am, Wednesday, 15'th Jul 2020
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses,
Is Moleculin Biotech (MBRX) Outperforming Other Medical Stocks This Year?
03:30pm, Friday, 03'rd Jul 2020
Is (MBRX) Outperforming Other Medical Stocks This Year?
